EMA: 5 product-specific guidances adopted [BE/BA News]

posted by Helmut Homepage – Vienna, Austria, 2018-08-03 16:52 (810 d 21:54 ago) – Posting: # 19133
Views: 2,991

Dear all,

today the EMA published another set of product-specific guidances (adopted by the CHMP 26 July, effective with 2 February 2019):
  1. Agomelatine tablet 25 mg
  2. Posaconazole gastro-resistant tablet 100 mg
  3. Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg
  4. Cholic acid capsules 50 mg and 250 mg
  5. Vismodegib hard capsule 150 mg

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
21,176 posts in 4,413 threads, 1,475 registered users;
online 7 (0 registered, 7 guests [including 4 identified bots]).
Forum time: Thursday 14:47 CEST (Europe/Vienna)

It is not so much that I have confidence in scientists being right,
but that I have so much in nonscientists being wrong.    Isaac Asimov

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz